Alto Neuroscience reported cash from operations of -$19.76M and free cash flow of -$19.76M for the quarter ended Jun 2026, down 43.4% year over year. This cash flow statement covers 14 quarters of results from Mar 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Net Income | -7.29M | -8.79M | -9.37M | -11.38M | -13.17M | -16.03M | -16.73M | -15.20M | -14.45M | -17.64M | -14.07M | -16.07M | -26.12M | -27.51M |
| Share-based Compensation | 0.48M | 1.26M | 0.54M | 0.61M | 2.18M | 1.89M | 2.00M | 1.57M | 1.97M | 2.00M | 2.19M | 1.95M | 2.82M | 3.55M |
| Gains from Investment Securities | -0.01M | -0.12M | -0.23M | -0.17M | 0.24M | 0.05M | 0.04M | |||||||
| Cash from Operations | -7.52M | -6.63M | -7.76M | -11.52M | -10.98M | -11.69M | -11.73M | -13.02M | -16.56M | -13.78M | -9.92M | -11.52M | -27.09M | -19.76M |
| Depreciation, Depletion & Amortization | ||||||||||||||
| Amortizatization of Intangibles | 0.07M | 0.07M | 0.07M | 0.07M | 0.07M | 0.05M | 0.21M | 0.19M | 0.19M | 0.20M | 0.20M | 0.20M | 0.20M | |
| Depreciation & Amortization (CF)Depreciation & Amortization | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M | 0.10M | 0.20M | 0.17M | 0.20M | 0.10M | ||||
| Change in Working Capital | ||||||||||||||
| Change in Account Payables | -0.65M | 1.44M | -0.64M | -0.78M | 1.12M | -0.25M | 0.41M | -0.76M | -0.27M | 0.32M | 0.46M | -0.30M | 1.49M | 0.65M |
| Change in Accured Expenses | 0.17M | -1.29M | 1.26M | -0.50M | 0.41M | 1.56M | 1.63M | 0.41M | -2.70M | 0.46M | 0.21M | 1.74M | -1.75M | 1.21M |
| Other Working Capital Changes | 0.46M | -0.39M | 0.08M | -0.45M | 1.78M | -0.12M | -0.74M | -0.45M | 1.69M | -0.51M | -0.63M | -0.66M | 4.13M | -1.78M |
| Investing Activities | ||||||||||||||
| Capital Expenditures | 0.02M | 0.05M | 0.04M | 0.35M | 0.32M | 0.24M | 1.00M | 0.51M | 0.02M | 3.71M | 0.94M | |||
| Cash from Investing Activities | -0.02M | -0.05M | -0.04M | -0.35M | -0.22M | -0.34M | -1.00M | -0.51M | -0.02M | -0.56M | ||||
| Financing Activities | ||||||||||||||
| Other financing activities | 0.04M | 0.11M | 0.03M | 137.58M | 0.52M | 0.18M | 0.01M | 0.07M | ||||||
| Debt Issuance and Repayment | ||||||||||||||
| Long-Term Debt Issuances | 1.30M | 1.30M | 19.69M | |||||||||||
| Long-Term Debt Repayments | 10.21M | |||||||||||||
| Change in Capital Stock | ||||||||||||||
| Net Equity Issued and Repurchased | 25.00M | 45.00M | ||||||||||||
| Misc. | ||||||||||||||
| Cash from Financing Activities | 25.00M | -0.05M | 0.05M | 43.13M | 134.56M | -0.23M | 1.32M | 0.05M | 9.13M | 0.61M | 0.15M | 50.19M | 114.94M | -0.27M |
| Exchange Rate Effect | -0.02M | -0.01M | 0.02M | 0.00M | -0.01M | -0.01M | -0.01M | 0.01M | -0.02M | -0.00M | -0.00M | -0.00M | -0.02M | 0.00M |
| Change in Cash | 17.44M | -6.75M | -7.74M | 31.26M | 123.35M | -12.27M | -11.42M | -13.47M | -7.47M | -13.17M | -9.77M | 38.67M | 87.28M | -20.03M |
| Free Cash Flow | -7.54M | -6.69M | -7.81M | -11.88M | -11.30M | -11.94M | -12.73M | -13.53M | -16.58M | -13.78M | -9.92M | -15.22M | -28.03M | -19.76M |
| Net Cash Flow | 17.45M | -6.74M | -7.76M | 31.26M | 123.35M | -12.27M | -11.41M | -13.48M | -7.45M | -13.17M | -9.77M | 38.67M | 87.29M | -20.03M |